After three months without a permanent leader in place, President Donald Trump looks set to name a new commissioner of the ...
Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival (RFS) when ...
Scientists’ ability to recapitulate the human brain in a dish has always been hindered by the inability to model the full ...
Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein ...
The oncology R&D organization, Sarah Cannon Research Institute (SCRI), announced a collaboration with Merck & Co. to bolster ...
Antibody platform business OmniAb continues to rack up the Big Pharma partnerships, with Eli Lilly signing off on ...
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint ...
Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, is handing pink slips to 20 staffers, ...
Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results